Additional Hetero Ring Containing Patents (Class 544/60)
-
Publication number: 20090143357Abstract: Substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division, also are disclosed.Type: ApplicationFiled: March 29, 2006Publication date: June 4, 2009Applicant: ICOS CORPORATIONInventors: Frank Diaz, Francine S. Farouz, Ryan Coatsworth Holcomb, Edward A. Kesicki, Hua Chee Ooi, Alexander Rudolph, Frank Stappenbeck, Eugene D. Thorsett, John Joseph Gaudino, Kimba Lee Fischer, Adam Wade Cook
-
Patent number: 7541359Abstract: Certain N-heteroarylpiperazinyl urea compounds of Formula (I), as defined in the specification, are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).Type: GrantFiled: June 28, 2006Date of Patent: June 2, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Richard Apodaca, J. Guy Breitenbucher, Kanaka Pattabiraman, Mark Seierstad, Wei Xiao
-
Publication number: 20090137550Abstract: This invention relates to a novel group of 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N?-substituted-N?-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.Type: ApplicationFiled: March 24, 2006Publication date: May 28, 2009Inventors: Jeffrey C. Boehm, John J. Taggart
-
Publication number: 20090137572Abstract: The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.Type: ApplicationFiled: May 26, 2005Publication date: May 28, 2009Inventors: Shudong Wang, Gavin Wood, Kenneth Duncan, Christopher Meades, Darren Gibson, Janice McLachlan, Peter Martin Fischer
-
Publication number: 20090131397Abstract: The present application is directed to a new class of isoxazoles and their use as estrogen modulators.Type: ApplicationFiled: October 31, 2008Publication date: May 21, 2009Inventors: Simon Bailey, Stephen Douglas Barrett, Larry Don Bratton, Stephen Alan Fakhoury, Sandra Marie Jennings, Lorna Helen Mitchell, Raj Kumar Raheja, Veerabahu Shanmugasundaram
-
Patent number: 7528162Abstract: The present invention relates to a group of novel 4,5-dihydro-1H-pyrazole derivatives which are potent cannabinoid (CB1) receptor antagonists with utility for the treatment of diseases connected with disorders of the cannabinoid system. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification. The invention also relates to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component.Type: GrantFiled: September 17, 2002Date of Patent: May 5, 2009Assignee: Solvay Pharmaceuticals, B.V.Inventors: Cornelis G. Kruse, Josephus H. M. Lange, Jacobus Tipker, Arnoldus H. J. Herremans, Herman H. Van Stuivenberg
-
Patent number: 7524842Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? or combinations thereof.Type: GrantFiled: January 16, 2007Date of Patent: April 28, 2009Assignee: Schering CorporationInventors: Brian J. Lavey, Joseph A. Kozlowski, Guowei Zhou, Ling Tong, Wensheng Yu, Michael K. C. Wong, Bandarpalle B. Shankar, Neng-Yang Shih, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Razia Rizvi, Lei Chen, De-Yi Yang, Robert Feltz, Seong Heon Kim
-
Publication number: 20090105215Abstract: The compounds of the present invention are of formula I: wherein A, R3, R4 is as defined herein, are useful as ligands for nicotinic receptors.Type: ApplicationFiled: April 6, 2007Publication date: April 23, 2009Inventors: Brian Herbert, Wenge Xie, Truc Minh Nguyen, Allen T. Hopper, Ashok Tehim
-
Patent number: 7517902Abstract: Disclosed are novel substituted indazole compounds, pharmaceutical compositions comprising such compounds, and methods of treatment comprising such compounds.Type: GrantFiled: December 4, 2006Date of Patent: April 14, 2009Assignee: Aventis Pharma S.A.Inventors: Frank Halley, Michel Tabart, Hervé Bouchard, Catherine Souaille, Alain Le Brun, Fabrice Viviani, Laurence Gauzy-Lazo, Pascal Desmazeau, Odile Angouillant-Boniface, Bruno Filoche-Romme
-
Publication number: 20090093455Abstract: The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.Type: ApplicationFiled: October 3, 2008Publication date: April 9, 2009Inventors: Johnny Yasuo NAGASAWA, Fabrice PIERRE, Mustapha HADDACH, Michael SCHWAEBE, Levan DARJANIA, Jeffrey P. WHITTEN
-
Patent number: 7514436Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.Type: GrantFiled: July 29, 2004Date of Patent: April 7, 2009Assignee: Xenon Pharmaceuticals Inc.Inventors: Heinz W. Gschwend, Vishnumurthy Kodumuru, Shifeng Liu, Rajender Kamboj
-
Publication number: 20090075980Abstract: Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.Type: ApplicationFiled: March 31, 2006Publication date: March 19, 2009Applicant: Coley Pharmaceutical Group, Inc.Inventors: David S. Hays, Michael E. Danielson, John F. Gerster, Shri Niwas, Ryan B. Prince, Tushar A. Kshirsagar, Philip D. Heppner, William H. Moser, Joan T. Moseman, Matthew R. Radmer, Maureen A. Kavanagh, Sarah A. Strong, Jason D. Bonk
-
Publication number: 20090075979Abstract: Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R2 is a phenyl group which has an ortho amine or aminomethyl substituent which is further substituted, and the other of B or R2 is also a cyclic group.Type: ApplicationFiled: December 29, 2006Publication date: March 19, 2009Inventors: Amjad Ali, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Cameron J. Smith, Adrian A. Dowst, Yi-Heng Chen
-
Patent number: 7501408Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. More particularly, the present invention provides compounds having Formula (I): wherein Q is thiomorpholinyl; and A, R5, R6, R7, R8, R9 and Ar are substituents.Type: GrantFiled: October 31, 2007Date of Patent: March 10, 2009Assignee: IRM LLCInventors: Hong Liu, Arnab Chatterjee, David C. Tully, Phillip Alper, Badry Bursulaya, Jianhua Guo, David H. Woodmansee, Daniel Mutnick, Donald S. Karanewsky, Yun He
-
Publication number: 20090062531Abstract: A compound of the formula (I): pharmaceutically acceptable salt or solvate thereof, wherein Y is a group of the formula: wherein Ring A is optionally substituted aryl or optionally substituted heteroaryl, X3 is COOR17 or the like Y is not optionally substituted phenyl which is substituted with the formula: —CR9R10X3 at the para position, R1 to R10 are each independently halogen, hydroxy, optionally substituted lower alkyl, optionally substituted aryl or the like, X1 is —O—, —S— or the like.Type: ApplicationFiled: May 23, 2006Publication date: March 5, 2009Inventor: Yasuhiko Kanda
-
Publication number: 20090054420Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).Type: ApplicationFiled: August 21, 2008Publication date: February 26, 2009Applicant: ABBOTT LABORATORIESInventors: Robert J. Altenbach, Lawrence A. Black, Sou-Jen Chang, Marlon D. Cowart, Ramin Faghih, Gregory A. Gfesser, Yi-Yin Ku, Huaqing Liu, Kirill A. Lukin, Diana L. Nersesian, Yu-ming Pu, Padam N. Sharma, Youssef L. Bennani, Michael P. Curtis
-
Publication number: 20090054642Abstract: The present invention relates to a novel benzamidine derivative, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzamidine derivative of the present invention effectively inhibits osteoclast differentiation at an extremely low concentration, and greatly increases the trabecular bone volume, and thus it can be advantageously used for the prevention and treatment of osteoporosis.Type: ApplicationFiled: January 31, 2007Publication date: February 26, 2009Applicant: DONGWHA PHARMACEUTICAL IND. CO., LTD.Inventors: Jei Man Ryu, Jin Soo Lee, Young Goo Jin, Ki Young Lee, Jae Hoon Park, Yun Ha Hwang, Sae Kwang Ku
-
Publication number: 20090048228Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable salts or tautomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.Type: ApplicationFiled: December 9, 2005Publication date: February 19, 2009Inventors: Barbara Attenni, Federica Ferrigno, Philip Jones, Raffaele Ingenito, Olaf Kinzel, Laura Llauger Bufi, Jesus Maria Ontoria, Giovanna Pescatore, Michael Rowley, Rita Scarpelli, Carsten Schultz
-
Patent number: 7491730Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK3 mammalian protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.Type: GrantFiled: August 1, 2003Date of Patent: February 17, 2009Assignee: Vertex Pharmaceuticals IncorporatedInventors: Cornelia J. Forster, Larry C. Park, Marion W. Wannamaker, Yung-Mae M. Yao
-
Publication number: 20090042866Abstract: The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production.Type: ApplicationFiled: November 23, 2005Publication date: February 12, 2009Inventors: William Lennox, Hongyan Qi, Duck-Hyung Lee, Soongyu Choi, Young-Choon Moon
-
Patent number: 7488727Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK3, Aurora2, and Syk mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.Type: GrantFiled: June 15, 2007Date of Patent: February 10, 2009Assignee: Vertex Pharmaceuticals IncorporatedInventors: John Cochran, Suganthini Nanthakumar, Edmund Harrington, Jian Wang
-
Publication number: 20090036434Abstract: The present invention relates to certain substituted aryl and heteroaryl derivative of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.Type: ApplicationFiled: June 2, 2005Publication date: February 5, 2009Applicant: Arena Pharmaceuticals, Inc.Inventors: Robert M. Jones, Graeme Semple, Yifeng Xiong, Young-Jun Shin, Albert S. Ren, Juerg Lehmann, Beatriz Fioravanti, Marca A. Bruce, Jin Sun Karoline Choi
-
Publication number: 20090029955Abstract: A pyridothienopyrimidine derivative of formula (I), or the pharmaceutically acceptable salts or N-oxides thereof are disclosed, as well as pharmaceutical compositions comprising said compounds and methods of treatment or prevention of a pathological condition or disease susceptible to amelioration by inhibition of phosphodiesterase 4 using said compounds are disclosed.Type: ApplicationFiled: November 30, 2005Publication date: January 29, 2009Inventors: Lluis Miquel Pages Santacana, Joan Taltavull Moll
-
Patent number: 7482341Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.Type: GrantFiled: September 29, 2005Date of Patent: January 27, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
-
Patent number: 7482340Abstract: Therapeutically active compounds of formula (I) or (II): wherein the variables in formulas (I) and (II) are defined in the description, and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na+/Ca2+ exchange mechanism.Type: GrantFiled: January 9, 2004Date of Patent: January 27, 2009Assignee: Orion CorporationInventors: Leena Otsomaa, Tuula Koskelainen, Arto Karjalainen, Sirpa Rasku, Piero Pollesello, Jouko Levijoki
-
Publication number: 20090018122Abstract: Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.Type: ApplicationFiled: August 27, 2004Publication date: January 15, 2009Inventors: Kyle J. Lindstrom, Hugues M.H. Martin, Bryon A. Merrill, Michael J. Rice, Joshua R. Wurst, Chad A. Haraldson, Tushar A. Kshirsagar, Philip D. Heppner, Shri Niwas, George W. Griesgraber, Matthew R. Radmer
-
Publication number: 20090018123Abstract: The present invention concerns recombinant DNA's comprising cDNA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNA's are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines.Type: ApplicationFiled: June 19, 2006Publication date: January 15, 2009Inventors: Milind D Sindkhedkar, Satish B. Bhavsar, Vijaykumar J. Patil, Prasad K. Deshpande, Mahesh V Patel
-
Publication number: 20090005355Abstract: The present invention is to provide a piperidine compound represented by the formula [I]: wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted benzene ring, R1 is hydrogen atom or a substituent for amino group, R2 is hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z is oxygen atom or —N(R3)—, R3 is hydrogen atom or an optionally substituted alkyl group, R4a and R4b may be the same or different, and each is hydrogen atom or an optionally substituted alkyl group, or may be bonded to each other at the both ends to form an alkylene group, or a pharmaceutically acceptable salt thereof, which has an excellent tachykinin receptor antagonistic action.Type: ApplicationFiled: July 1, 2005Publication date: January 1, 2009Applicant: Tanabe Seiyaku Co., Ltd.Inventors: Tsutomu Miyake, Takeshi Yamanaka, Hidetoshi Asai, Yoshihiro Terakawa
-
Publication number: 20090005370Abstract: The present invention is concerned isoxazole-imidazole derivatives having affinity and selectivity for GABA A ?5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use for enhancing cognition or for the treatment of cognitive disorders like Alzheimer's disease. In particular, the present invention is concerned with aryl-isoxazol-4-yl-imidazole derivatives of formula I wherein R1, R2 and R3 are as described in the specification.Type: ApplicationFiled: June 16, 2008Publication date: January 1, 2009Inventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Andrew Thomas
-
Publication number: 20080306055Abstract: Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease, and pain related disorders. The compounds are melanin concentrating hormone receptor 1 (MCHr1) antagonists.Type: ApplicationFiled: December 19, 2005Publication date: December 11, 2008Applicant: ASTRAZENECA ABInventors: Bryan Egner, Fabrizio Giordanetto, Tord Inghardt
-
Publication number: 20080293705Abstract: Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described.Type: ApplicationFiled: August 6, 2008Publication date: November 27, 2008Applicant: Endacea, Inc.Inventors: Constance Neely Wilson, John J. Partridge
-
Patent number: 7452879Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.Type: GrantFiled: October 5, 2006Date of Patent: November 18, 2008Assignee: Rigel Pharmaceuticals, Inc.Inventors: Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
-
Publication number: 20080280889Abstract: The present invention is directed to compounds which contain substituted pyridazines and pyrimidines moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration (if the compounds of the invention.Type: ApplicationFiled: April 5, 2005Publication date: November 13, 2008Inventors: Mark T. Bilodeau, Peter C. Chua, Nicholas D.P. Cosford, Jacob M. Hoffman, Johnny Yasuo Nagasawa
-
Publication number: 20080280890Abstract: The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.Type: ApplicationFiled: February 15, 2008Publication date: November 13, 2008Inventor: Ghanshyam Patil
-
Patent number: 7449457Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.Type: GrantFiled: December 2, 2002Date of Patent: November 11, 2008Assignee: Eli Lilly and CompanyInventors: David Kent Herron, Sajan Joseph, Angela Lynn Marquart, John Joseph Masters, David Mendel, Gerald Floyd Smith, Anne Louise Tebbe, Philip Parker Waid, Michael Robert Wiley, Ying Kwong Yee
-
Patent number: 7449456Abstract: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.Type: GrantFiled: June 26, 2003Date of Patent: November 11, 2008Assignee: Astellas Pharma, Inc.Inventors: Shinya Nagashima, Hiroshi Nagata, Masahiro Iwata, Masaki Yokota, Hiroyuki Moritomo, Eiichi Nakai, Sadao Kuromitsu, Keiko Ohga, Makoto Takeuchi
-
Patent number: 7449477Abstract: The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.Type: GrantFiled: November 22, 2004Date of Patent: November 11, 2008Assignee: Eli Lilly and CompanyInventors: David Anthony Barda, Kenneth James Henry, Jr., Jianping Huang, Sajan Joseph, Ho-Shen Lin, Michael Enrico Richett
-
Publication number: 20080275021Abstract: The invention relates to pyrrolidine derivatives of formula wherein R1, R2, R3, n, and o are defined in the specification and to pharmaceutically active acid-addition salts thereof. Compounds of formula I have a high affinity simultaneously to both the NK1 and the NK3 receptors (dual NK1/NK3 receptor antagonists), useful in the treatment of schizophrenia.Type: ApplicationFiled: April 14, 2008Publication date: November 6, 2008Inventors: Caterina Bissantz, Torsten Hoffmann, Philippe Jablonski, Henner Knust, Mathias Nettekoven, Hasane Ratni, Xihan Wu
-
Patent number: 7446104Abstract: Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.Type: GrantFiled: October 18, 2007Date of Patent: November 4, 2008Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Richard Apodaca, Xiaohu Deng, Jill A. Jablonowski, Neelakandha Mani, Chennagiri R. Pandit, Wei Xiao
-
Publication number: 20080261944Abstract: The present invention relates to indole compounds of the formula (I): wherein R1, R2, R3, R4, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.Type: ApplicationFiled: June 8, 2005Publication date: October 23, 2008Inventors: Stefania Colarusso, Immacolata Conte, Joerg Habermann, Frank Narjes, Simona Ponzi
-
Patent number: 7439371Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.Type: GrantFiled: July 11, 2006Date of Patent: October 21, 2008Assignee: Allergan, Inc.Inventors: Julie A. Wurster, Richard C. Yee
-
Publication number: 20080255105Abstract: A compound which is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof wherein: R1 is a C1-C6 alkyl group or a moiety -A1, -L1-A1, -A1-A1?, -L1-A1-A1?, -A1-L1-A1?, -A1-Y1-A1?, -A1-Het1-A1?, -L1-A1-Y1-A1?, -L1-A1-Het1-A1?, -L1-Het1-A1, -L1-Y1-A1, -L1-Y1-Het1-A1, -L1-Het1-Y1-A1, -L1-Y1-Het1-L1?, -A1-Y1-Het1-A1?, -A1-Het1-Y1-A1?, -A1-Het1-L1-A1?, -A1-L1-Het1-A1? or -L1-Het1-L1?; -A and B are the same or different and each represent a direct bond or a —CO—NR?—, —NR?—CO—, —NR?—CO2—, —CO—, —NR?—CO—NR?—, —NR?—S(O)2—, —S(O)2—NR?—, —SO2—, —NR?—, —NR?—CO—CO—, —CO—O—, —O—CO—, —(C1-C2 alkylene)-NR?— or —(C1-C2 hydroxyalkylene)-NR?-moiety, wherein R? and R? are the same or different and each represent hydrogen or C1-C4 alkyl; —R2 and R3 are the same or different and each represent C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy or halogen; n and m are the same or different and each represent 0 or 1; R4 is a C1-C6 alkyl group or a moiety -A4, -L4-A4, -A4-A4?, -L4-A4-A4?, -A4-L4Type: ApplicationFiled: September 18, 2006Publication date: October 16, 2008Inventors: Christopher James Wheelhouse, Alexander James Floyd Thomas, David John Bushnell, James Lumley, James Iain Salter, Malcolm Clive Carter, Neil Mathews, Christopher John Pilkington, Richard Martyn Angell
-
Patent number: 7435726Abstract: This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.Type: GrantFiled: May 14, 2001Date of Patent: October 14, 2008Assignee: Celgene CorporationInventors: Jerome B. Zeldis, Andrew L. Zeitlin, Sol Barer
-
Patent number: 7432276Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.Type: GrantFiled: December 27, 2006Date of Patent: October 7, 2008Assignee: CV Therapeutics, Inc.Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun, Melanie Boze
-
Patent number: 7427612Abstract: A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.Type: GrantFiled: September 2, 2004Date of Patent: September 23, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Daniela Alberati-Giani, Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stalder
-
Publication number: 20080221088Abstract: The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5?-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.Type: ApplicationFiled: June 23, 2006Publication date: September 11, 2008Inventors: Vijay Kumar Potluri, Saibal Kumar Das, Pradip Kumar Sasmal, Javed Iqbal, Parimal Misra, Ranjan Chakrabarti, Rashmi Talwar
-
Patent number: 7423045Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.Type: GrantFiled: June 28, 2006Date of Patent: September 9, 2008Assignee: CV Therapeutics, Inc.Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun
-
Publication number: 20080207607Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.Type: ApplicationFiled: November 20, 2007Publication date: August 28, 2008Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgurtel, Hongbo Deng, Brian M. Gallagher, Irving Sucholeiki, Arthur Taveras
-
Publication number: 20080207606Abstract: Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell-damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever.Type: ApplicationFiled: February 8, 2008Publication date: August 28, 2008Applicant: ORCHID RESEARCH LABORATORIES LIMITED.Inventors: Akella Satya Surya Visweswara Srinivas, Ravikumar Tadiparthi, Ganapavarapu Veera Raghava Sharma, Sappanimuthu Thirunavukkarasu, Durairaj Peter Bhakiaraj, Virendra Kachhadia, Kilambi Narsimhan, Sathya Narayana Thara, Sriram Rajagopal, Gaddam Om Reddy, Sukunath Narayanan, Venkatesan Parameswaran, Venkatesan Janarthanam, Maruthikumar Narayanam, Sathyanarayana Gadde, Uma Ramachandran
-
Patent number: 7414047Abstract: Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.Type: GrantFiled: October 21, 2003Date of Patent: August 19, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: Richard L. Apodaca, Jill A. Jablonowski, Kiev S. Ly, Chandravadan R. Shah, Devin M. Swanson, Wei Xiao